case_images: PMC10710141_01
case_images: Timeline of historical and clinical events. 5-MeO-DMT, 5-methoxy-N,N-dimethyltryptamine (experimental treatment); COVID-19, coronavirus disease pandemic; CPT, cognitive processing therapy (cognitive behavioral therapy); PE, prolonged exposure (cognitive behavioral therapy); SARI, serotonin antagonist and reuptake inhibitor (trazadone); SCID-5, Structured Clinical Interview for DSM-5 (diagnostic assessment); SIT, stress inoculation therapy (cognitive behavioral therapy); SSRI, selective serotonin reuptake inhibitor (sertraline); T0, baseline; T1, 24 h follow-up; T2, 1 month follow-up; T3, 3 months follow-up; T4, 6 months follow-up; T5, 12 months follow-up.
case_images: fpsyt-14-1271152-g001.jpg
case_images: PMC10710141_01_fpsyt-14-1271152-g001.jpg
case_images: fig1
case_images: See Figure 1 for a timeline of events.
case_images: Vital signs taken before and after 5-MeO-DMT dosing. 5-MeO-DMT, 5-methoxy-N,N-dimethyltryptamine; DBP, diastolic blood pressure (mmHg); HR, heart rate (bmp); SBP, systolic blood pressure (mmHg); SpO2, peripheral blood oxygenation (%).
case_images: fpsyt-14-1271152-g002.jpg
case_images: PMC10710141_01_fpsyt-14-1271152-g002.jpg
case_images: fig2
case_images: See Table 1 and Figure 2.
case_images: Mystical effects of 5-MeO-DMT. Blue dotted line indicates the cut-off point for a complete mystical experience (>=60% of total scores across factors). 5-MeO-DMT, 5-methoxy-N,N-dimethyltryptamine; MEQ-30, Mystical Experience Questionnaire.
case_images: fpsyt-14-1271152-g003.jpg
case_images: PMC10710141_01_fpsyt-14-1271152-g003.jpg
case_images: fig3
case_images: See Figure 3 for details.
case_images: Change in PTSD symptoms by time point [(A), line graph]. Change in PTSD symptoms across time [(B), bar chart]. Change in hopelessness symptoms by time point [(C) line graph]. Change in hopelessness symptoms across time [(D), bar chart]. BHS, Beck Hopelessness Scale; CB, cluster B (thought intrusion); CC, cluster C (stimuli avoidance); CD, cluster D (negative mood and cognitions); CE, cluster E (altered reactivity); EF, expectations about the future (hopelessness); FF, feelings about the future (hopelessness); LM, loss of motivation (hopelessness); PCL-5, PTSD Checklist for DSM-5; PTSD, post-traumatic stress disorder; SS, symptom severity; T0, baseline; T1, 24 h follow-up; T2, 1 month follow-up; T3, 3 months follow-up; T4, 6 months follow-up; T5, 12 months follow-up.
case_images: fpsyt-14-1271152-g004.jpg
case_images: PMC10710141_01_fpsyt-14-1271152-g004.jpg
case_images: fig4
case_images: See Table 2 and Figures 4A,B. See Table 2 and Figures 4C,D.